Program overview
Context
Indication: Cholangiocarcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: Taiho Oncology, .
Futibatinib is flagged as operational burden signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Cholangiocarcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: Taiho Oncology, .
Registry: 0/5
Timeline: 1/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 2/5
https://clinicaltrials.gov/study/NCT02052778
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT02052778 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal |